Head to head

GentleMax Pro vs Motus PRO (2026)

Compare purchase costs, running costs and the evidence behind each device.

Read the comparison overview

Purchase cost: The catalog lists $69,950 (dealer-described unused 2019 unit with three handpieces) for GentleMax Pro. No new-price range is on file for Motus PRO. Check the source notes and request current quotes.
Technology: GentleMax Pro: Nd:YAG. Motus PRO: Alexandrite.
Practice fit: GentleMax Pro: dual-wavelength platform. Motus PRO: alexandrite laser (in-motion). Check each model’s US regulatory status and labeled indications for your intended use.

Device A

Dual-wavelength platform

View full device profile →

Device B

Alexandrite laser (in-motion)

View full device profile →

Price comparison

Price comparison: Candela GentleMax Pro vs DEKA Motus PRO
Attribute	Candela GentleMax Pro	DEKA Motus PRO
New price range	$69,950 (dealer-described unused 2019 unit with three handpieces)Reported source: Dealer quote · Oct 7, 2026	Not published
Used price reference	28975-67000 (core cluster 37700-57500)Reported source: Used listing · Aug 30, 2026	Not published
Payback calculator	View ROI calculator	View cost details
Next step	Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models. Browse current models

New price range

Candela GentleMax Pro: $69,950 (dealer-described unused 2019 unit with three handpieces)Reported source: Dealer quote · Oct 7, 2026
DEKA Motus PRO: Not published

Used price reference

Candela GentleMax Pro: 28975-67000 (core cluster 37700-57500)Reported source: Used listing · Aug 30, 2026
DEKA Motus PRO: Not published

Payback calculator

Candela GentleMax Pro: View ROI calculator
DEKA Motus PRO: View cost details

Next step

Candela GentleMax Pro

Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models.

Browse current models

DEKA Motus PRO

Supplies & running costs

Supplies & running costs: Candela GentleMax Pro vs DEKA Motus PRO
Attribute	Candela GentleMax Pro	DEKA Motus PRO
Supplies & restrictions	Read supply costs & requirements Budget for DCD cryogen and applicable replacement parts. Current US manufacturer prices for cryogen, distance gauges and flashlamps, and cryogen usage for a specified treatment, have not been verified here. The catalog therefore does not establish a per-treatment cost. Dealer quote · Aug 30, 2026 Supply restrictions: no published lock — no electronic gating documented View running-cost details	Historical Motus-family replacement-part prices are recorded, but exact Motus PRO compatibility, current offers and per-treatment supply costs are not verified. Dealer quote · Aug 30, 2026 View running-cost details

Supplies & restrictions

Candela GentleMax Pro: Read supply costs & requirements
Budget for DCD cryogen and applicable replacement parts. Current US manufacturer prices for cryogen, distance gauges and flashlamps, and cryogen usage for a specified treatment, have not been verified here. The catalog therefore does not establish a per-treatment cost.
Dealer quote · Aug 30, 2026
Supply restrictions: no published lock — no electronic gating documented
View running-cost details
DEKA Motus PRO: Historical Motus-family replacement-part prices are recorded, but exact Motus PRO compatibility, current offers and per-treatment supply costs are not verified.
Dealer quote · Aug 30, 2026
View running-cost details

FDA status & indications

FDA status & indications: Candela GentleMax Pro vs DEKA Motus PRO
Attribute	Candela GentleMax Pro	DEKA Motus PRO
FDA status & indication	FDA record cited — see scopeK140122, K201111 Record scope: Family clearance: K140122 (CANDELA GENTLEMAX FAMILY, Candela Corp., decision 9 May 2014) and K201111 (GentleMax Pro Plus, Candela, decision 26 May 2020, family). Checked 4 Sep 2026. Read FDA indication wording “The GentleMAX Family of Laser Systems is indicated for the following at the specified wavelength: 7S5nm Temporary hair reduction. Stable long-term or permanent reduction through selective targeting of melanin in hair follicles. Permanent hair reduction isdefined as long-term stable reduction in the number of hairs regrowing after a treatment regime. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. On all skin types (Fitzpatrick [- VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. The photocoagulation of dermatological vascular lesions (such as pant-wine stains, hemangiomas, telangiectasias) 1064nm Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. Permanent hair reduction isdefined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. The lasers are indicated on all skin types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of pigmented and vascular lesions such as but not limited to port wine stains, hemangioma, warts, telangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), cafd au ]ait macules, seborrheic keratosis, nevi, chloasma, verrucae, skin tags, keratosis, tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plaques. The laser is indicated for pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles. 1064nm Temporary increase of clear nail in patients with onychomycosis (e.g., derniatophytes, Trichophyton rubrum and T. mentagrophytes, and for yeast Candida Albicans, etc.)”	FDA record cited — see scopeK241459 Record scope: 510(k): K241459 (decision 21 Jun 2024). Checked 4 Sep 2026. Read FDA indication wording “The MOTUS PRO family is a medical device laser family intended for: Alexandrite 755nm laser source: • Temporary hair reduction. • Stable long term or permanent hair reduction through selective targeting of melanin in hair follicles. • Permanent hair reduction is defined as the long term, stable reduction in the number of hairs regrowing when measured at 6,9 and 12 months after the completion of a treatment regime on all skin types (Fitzpatrick I-VI) including tanned skin. • Treatment of benign pigmented lesions. • Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. • Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venous lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), café au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. • The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. • The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles.”

FDA status & indication

Candela GentleMax Pro: FDA record cited — see scopeK140122, K201111
Record scope: Family clearance: K140122 (CANDELA GENTLEMAX FAMILY, Candela Corp., decision 9 May 2014) and K201111 (GentleMax Pro Plus, Candela, decision 26 May 2020, family). Checked 4 Sep 2026.
Read FDA indication wording
“The GentleMAX Family of Laser Systems is indicated for the following at the specified wavelength: 7S5nm Temporary hair reduction. Stable long-term or permanent reduction through selective targeting of melanin in hair follicles. Permanent hair reduction isdefined as long-term stable reduction in the number of hairs regrowing after a treatment regime. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. On all skin types (Fitzpatrick [- VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. The photocoagulation of dermatological vascular lesions (such as pant-wine stains, hemangiomas, telangiectasias) 1064nm Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. Permanent hair reduction isdefined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. The lasers are indicated on all skin types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of pigmented and vascular lesions such as but not limited to port wine stains, hemangioma, warts, telangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), cafd au ]ait macules, seborrheic keratosis, nevi, chloasma, verrucae, skin tags, keratosis, tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plaques. The laser is indicated for pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles. 1064nm Temporary increase of clear nail in patients with onychomycosis (e.g., derniatophytes, Trichophyton rubrum and T. mentagrophytes, and for yeast Candida Albicans, etc.)”
DEKA Motus PRO: FDA record cited — see scopeK241459
Record scope: 510(k): K241459 (decision 21 Jun 2024). Checked 4 Sep 2026.
Read FDA indication wording
“The MOTUS PRO family is a medical device laser family intended for: Alexandrite 755nm laser source: • Temporary hair reduction. • Stable long term or permanent hair reduction through selective targeting of melanin in hair follicles. • Permanent hair reduction is defined as the long term, stable reduction in the number of hairs regrowing when measured at 6,9 and 12 months after the completion of a treatment regime on all skin types (Fitzpatrick I-VI) including tanned skin. • Treatment of benign pigmented lesions. • Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. • Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venous lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), café au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. • The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. • The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles.”

Which chains run each

Which chains run each: Candela GentleMax Pro vs DEKA Motus PRO
Attribute	Candela GentleMax Pro	DEKA Motus PRO
Chain adoption	3 recorded pairings	0 recorded pairings
Chains using it	Milan Laser Hair Removal(Confirmed) SEV Laser(Confirmed) Body Details(Confirmed)	—
Approved reviews	0	0

Chain adoption

Candela GentleMax Pro: 3 recorded pairings
DEKA Motus PRO: 0 recorded pairings

Chains using it

Candela GentleMax Pro: Milan Laser Hair Removal(Confirmed)
SEV Laser(Confirmed)
Body Details(Confirmed)
DEKA Motus PRO: —

Approved reviews

Candela GentleMax Pro: 0
DEKA Motus PRO: 0

Specs and platform

Specs and platform: Candela GentleMax Pro vs DEKA Motus PRO
Attribute	Candela GentleMax Pro	DEKA Motus PRO
Manufacturer	Candela	DEKA
Built by (OEM)	Candela Corporation	DEKA M.E.L.A. S.r.l.
Category	Dual-wavelength platform	Alexandrite laser (in-motion)
Technology	755nm alex + 1064nm Nd:YAG (Nd:YAG)	755 nm alexandrite + 1064 nm Nd:YAG with Moveo and traditional delivery (Alexandrite)
Launch year	2013	—
Status	Discontinued	Current
Manufacturing relationship evidence	No separate manufacturing-relationship record linked.	No separate manufacturing-relationship record linked.

Manufacturer

Candela GentleMax Pro: Candela
DEKA Motus PRO: DEKA

Built by (OEM)

Candela GentleMax Pro: Candela Corporation
DEKA Motus PRO: DEKA M.E.L.A. S.r.l.

Current alternatives

Current catalog models in related categories. Confirm availability and configuration with the supplier.

No current alternatives identified in the catalog yet. Browse current models

Get a free recommendation Browse by goal

Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.